NZ737851A - T-cell receptor specific antibodies - Google Patents

T-cell receptor specific antibodies

Info

Publication number
NZ737851A
NZ737851A NZ737851A NZ73785116A NZ737851A NZ 737851 A NZ737851 A NZ 737851A NZ 737851 A NZ737851 A NZ 737851A NZ 73785116 A NZ73785116 A NZ 73785116A NZ 737851 A NZ737851 A NZ 737851A
Authority
NZ
New Zealand
Prior art keywords
cell receptor
chains
tcr
specific antibodies
receptor specific
Prior art date
Application number
NZ737851A
Inventor
Dolores Schendel
Slavoljub Milosevic
Tanja Herrmann
Michaela Kügler
Original Assignee
Medigene Immunotherapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Immunotherapies Gmbh filed Critical Medigene Immunotherapies Gmbh
Publication of NZ737851A publication Critical patent/NZ737851A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to an antibody or binding fragment thereof that binds to a fraction of T cell receptor variable alpha (TCR Vα) chains comprising at least two different TCR Vα chains but less than all TCR Vα chains or that binds to a fraction of T cell receptor variable beta (TCR Vβ) chains comprising at least two different TCR Vβ chains but less than all TCR Vβ chains.
NZ737851A 2015-06-01 2016-06-01 T-cell receptor specific antibodies NZ737851A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15170154 2015-06-01
PCT/EP2016/062370 WO2016193301A1 (en) 2015-06-01 2016-06-01 T-cell receptor specific antibodies

Publications (1)

Publication Number Publication Date
NZ737851A true NZ737851A (en) 2019-08-30

Family

ID=53298194

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ737851A NZ737851A (en) 2015-06-01 2016-06-01 T-cell receptor specific antibodies

Country Status (14)

Country Link
US (1) US20180256716A1 (en)
EP (1) EP3303389A1 (en)
JP (1) JP2018517712A (en)
KR (1) KR20180020202A (en)
CN (1) CN108026171A (en)
AU (1) AU2016273215B2 (en)
BR (1) BR112017025332A2 (en)
CA (1) CA2987877A1 (en)
EA (1) EA201792662A1 (en)
HK (1) HK1253695A1 (en)
MX (1) MX2017015619A (en)
NZ (1) NZ737851A (en)
PH (1) PH12017502190A1 (en)
WO (1) WO2016193301A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303591B1 (en) 2015-06-01 2019-04-03 Medigene Immunotherapies GmbH T cell receptor library
JP2018517711A (en) 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー Methods for producing antibodies against cell surface proteins
TWI772282B (en) 2015-12-23 2022-08-01 德商梅迪基因免疫治療公司 Dendritic cell composition
CN107827959B (en) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 Identify the TCR and application thereof of hepatitis B (HBV) surface antigen S 183-91 epitopes
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) * 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3906057A4 (en) * 2019-01-04 2022-09-14 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020156335A1 (en) * 2019-01-29 2020-08-06 上海交通大学 Chimeric antigen receptor and use thereof
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
JP7737306B2 (en) * 2019-02-21 2025-09-10 マレンゴ・セラピューティクス，インコーポレーテッド Multifunctional molecules that bind to T cells and their use for treating autoimmune disorders
CN114126714A (en) * 2019-02-21 2022-03-01 马伦戈治疗公司 Anti-TCR antibody molecules and their uses
CN119661722A (en) 2019-02-21 2025-03-21 马伦戈治疗公司 Multifunctional molecules that bind to T cell-associated cancer cells and their uses
SG11202109056TA (en) * 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
CN112409474B (en) * 2019-08-23 2023-02-28 香雪生命科学技术（广东）有限公司 A high-affinity TCR that recognizes the SSX2 antigen
EP4058483A4 (en) * 2019-11-14 2023-11-15 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20230108300A1 (en) * 2020-01-29 2023-04-06 The Trustees Of The University Of Pennsylvania Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease
CN112147326B (en) * 2020-09-04 2022-04-08 北京大学 An accurate detection kit for tumor immune cell subset typing
EP4255482A1 (en) * 2020-12-01 2023-10-11 The Johns Hopkins University Methods and materials for treating t cell cancers
JP2024509027A (en) * 2020-12-18 2024-02-29 アブリンクス エン．ヴェー． T cell recruitment polypeptide based on TCR alpha/beta reactivity
AU2024264260A1 (en) * 2023-04-27 2025-11-13 Marengo Therapeutics, Inc. Combination therapies using molecules binding to tcr

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169938A (en) * 1987-04-25 1992-12-08 Kyowa Hakko Kogyo Co., Ltd. Anti-T cell receptor γ-chain monoclonal antibody
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
WO1991007508A1 (en) * 1989-11-15 1991-05-30 National Jewish Center For Immunology And Respiratory Medicine Method for measuring t-cell surface antigens in humans
WO1994004686A1 (en) 1992-08-21 1994-03-03 Biogen, Inc. Tat-derived transport polypeptides
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
ES2165851T3 (en) 1991-11-25 2002-04-01 Enzon Inc MULTIVALENT PROTEINS THAT JOIN ANTIGENS.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4213586B2 (en) 2001-09-13 2009-01-21 株式会社抗体研究所 Camel antibody library production method
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2501722A4 (en) * 2009-11-19 2013-05-01 Univ Singapore METHOD FOR PRODUCING MONOCLONAL ANTIBODIES LIKE T-LYMPHOCYTE RECEPTORS AND USES THEREOF
CN102295702B (en) * 2011-08-26 2014-01-29 中国科学院微生物研究所 Preparation method of specific single-chain antibody aimed at T cell receptor variable range
UY34317A (en) * 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß

Also Published As

Publication number Publication date
EA201792662A1 (en) 2018-04-30
WO2016193301A1 (en) 2016-12-08
KR20180020202A (en) 2018-02-27
AU2016273215B2 (en) 2019-04-11
CA2987877A1 (en) 2016-12-08
EP3303389A1 (en) 2018-04-11
JP2018517712A (en) 2018-07-05
HK1253695A1 (en) 2019-06-28
BR112017025332A2 (en) 2018-07-31
US20180256716A1 (en) 2018-09-13
PH12017502190A1 (en) 2018-06-11
CN108026171A (en) 2018-05-11
MX2017015619A (en) 2018-08-15
AU2016273215A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
NZ737851A (en) T-cell receptor specific antibodies
CY1123409T1 (en) ANTIBODIES AGAINST ICOS (INDUCIBLE T-CELL CO-STIMULATOR)
PH12018501042A1 (en) Antibodies and antibody fragments for site-specific conjugation
MX2023006482A (en) Bispecific antibodies specific for a costimulatory tnf receptor.
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
IL263083A (en) Single chain variable fragment cd3 binding proteins
EP3969471A4 (en) IMMUNE CELL RECEPTORS INCLUDING CD4 BINDING FRACTIONS
SG11202100170RA (en) Antibody molecules that bind pd-l1 and cd137
PL3241561T3 (en) Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
IL250321A0 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
ZA202002966B (en) T-cell receptor (tcr)-binding antibodies and uses thereof
ZA201905519B (en) Improved antigen binding receptor formats
NZ742290A (en) Binding molecules that inhibit cancer growth
MX378730B (en) High-throughput nucleotide library sequencing
DK3328888T5 (en) ANTI-PSMA antibodies, bispecific antigen binding molecules that bind PSMA AND and CD3, and uses thereof
EP3352760A4 (en) CD3 BINDING POLYPEPTIDES
PH12016501339A1 (en) Novel anti-netrin-1 antibody
WO2017075045A3 (en) Antibodies to b7-h1
SG10202010600SA (en) T cell receptor like antibodies that bind to p53-mhc class i complex
PH12015502807B1 (en) Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
EA201991922A1 (en) DESIGNED POLYPEPTIDES BINDING A TRANSFERRIN RECEPTOR
GB201808589D0 (en) Single domain antibodies that bind CD137
GB201818283D0 (en) Antibody molecules that bind PD-L1 and CD137
GB201811405D0 (en) Antibody molecules that bind PD-L1 and CD137

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed